IGM-7354 is a targeted IL-15 immune stimulating antibody for the treatment of patients with solid and hematologic malignancies. The antibody binding domains of IGM-7354 target PD-L1 on the surface of cells such as cancer cells, to selectively deliver IL-15 in the region of those PD-L1 expressing cells. We believe IGM-7354 may be able to enhance the immune system’s activity in the tumor microenvironment and may also potentially reduce toxicities of this type of therapy in other regions of the body

IGM plans to file an IND application in 2022 with the U.S. Food and Drug Administration (FDA) for IGM-7354 to begin clinical testing initially in solid tumors, followed potentially by studies in hematologic malignancies.